|
1）Marsland BJ, Yadava K, Nicod LP. The airway microbiome and disease. Chest. 2013; 144: 632-7
|
|
|
|
2）Schuster SC. Next-generation sequencing transforms today's biology. Nat Methods. 2008; 5: 16-8
|
|
|
|
|
|
3）Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012; 486: 207-14
|
|
|
|
|
|
4）Han MK, Huang YJ, Lipuma JJ, et al. Significance of the microbiome in obstructive lung disease. Thorax. 2012; 67: 456-63
|
|
|
|
|
|
5）van Nimwegen FA, Penders J, Stobberingh EE, et al. Mode and place of delivery, gastrointestinal microbiota, and their influence on asthma and atopy. J Allergy Clin Immunol. 2011; 128: 948-55.e1-3
|
|
|
|
|
|
6）Vael C, Vanheirstraeten L, Desager KN, et al. Denaturing gradient gel electrophoresis of neonatal intestinal microbiota in relation to the development of asthma. BMC Microbiol. 2011; 11: 68
|
|
|
|
|
|
7）Penders J, Thijs C, van den Brandt PA, et al. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. Gut. 2007; 56: 661-7
|
|
|
|
|
|
8）Thavagnanam S, Fleming J, Bromley A, et al. A meta-analysis of the association between Caesarean section and childhood asthma. Clin Exp Allergy. 2008; 38: 629-33
|
|
|
|
|
|
9）Penders J, Thijs C, Vink C, et al. Factors inflen-cing the composition of the intestinal microbiota in early infancy. Pediatrics. 2006; 118: 511-21
|
|
|
|
|
|
10）Bisgaard H, Hermansen MN, Buchvald F, et al. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med. 2007; 357: 1487-95
|
|
|
|
|
|
11）Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PloS One. 2010; 5: e8578
|
|
|
|
|
|
12）Huang YJ, Nelson CE, Brodie EL, et al. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J Allergy Clin Immunol. 2011; 127: 372-81.e1-3
|
|
|
|
|
|
13）Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010; 182: 598-604
|
|
|
|
|
|
14）Martinez FJ, Han MK, Flaherty K, et al. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert Rev Anti Infect Ther. 2006; 4: 101-24
|
|
|
|
|
|
15）Rosell A, Monso E, Soler N, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med. 2005; 165: 891-7
|
|
|
|
|
|
16）Sze MA, Dimitriu PA, Hayashi S, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 185: 1073-80
|
|
|
|
|
|
17）Pragman AA, Kim HB, Reilly CS, et al. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS One. 2012; 7: e47305
|
|
|
|
|
|
18）Huang YJ, Kim E, Cox MJ, et al. A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations. Omics. 2010; 14: 9-59
|
|
|
|
|
|
19）Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS One. 2011; 6: e16384
|
|
|
|
|
|
20）Bye MR, Ewig JM, Quittell LM. Cystic fibrosis. Lung. 1994; 172: 251-70
|
|
|
|
|
|
21）Yamashiro Y, Shimizu T, Oguchi S, et al. The estimated incidence of cystic fibrosis in Japan. J Pediatr Gastroenterol Nutr. 1997; 24: 544-7
|
|
|
|
|
|
22）Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev. 2010; 23: 299-323
|
|
|
|
|
|
23）Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev. 1996; 60: 539-74
|
|
|
|
|
|
24）van der Gast CJ, Walker AW, Stressmann FA, et al. Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities. ISME J. 2011; 5: 780-91
|
|
|
|
|
|
25）Tunney MM, Klem ER, Fodor AA, et al. Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis. Thorax. 2011; 66: 579-84
|
|
|
|
|
|
26）Price KE, Hampton TH, Gifford AH, et al. Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation. Microbiome. 2013; 1: 27
|
|
|
|
|
|
27）Cox MJ, Allgaier M, Taylor B, et al. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS One. 2010; 5: e11044
|
|
|
|
|
|
28）Carmody LA, Zhao J, Schloss PD, et al. Changes in cystic fibrosis airway microbiota at pulmonary exacerbation. Ann Am Thorac Soc. 2013; 10: 179-87
|
|
|
|
|
|
29）Han MK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014; 2: 548-56
|
|
|
|
|
|
30）Charlson ES, Diamond JM, Bittinger K, et al. Lung-enriched organisms and aberrant bacterial and fungal respiratory microbiota after lung transplant. Am J Respir Crit Care Med. 2012; 186: 536-45
|
|
|
|
|
|
31）Borewicz K, Pragman AA, Kim HB, et al. Longitudinal analysis of the lung microbiome in lung transplantation. FEMS Microbiol Lett. 2013; 339: 57-65
|
|
|
|
|
|
32）Nakajima T, Palchevsky V, Perkins DL, et al. Lung transplantation: infection, inflammation, and the microbiome. Semin Immunopathol. 2011; 33: 135-56
|
|
|
|
|
|
33）Iwai S, Huang D, Fong S, et al. The lung microbiome of Ugandan HIV-infected pneumonia patients is compositionally and functionally distinct from that of San Franciscan patients. PLoS One. 2014; 9: e95726
|
|
|
|
|